Lineage Cell Therapeutics (LCTX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 0.25.
- Lineage Cell Therapeutics' Equity Ratio fell 6334.53% to 0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25, marking a year-over-year decrease of 6334.53%. This contributed to the annual value of 0.69 for FY2024, which is 1027.55% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported Equity Ratio of 0.25 as of Q3 2025, which was down 6334.53% from 0.53 recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Equity Ratio ranged from a high of 0.93 in Q2 2021 and a low of 0.25 during Q3 2025
- In the last 5 years, Lineage Cell Therapeutics' Equity Ratio had a median value of 0.63 in 2023 and averaged 0.65.
- As far as peak fluctuations go, Lineage Cell Therapeutics' Equity Ratio soared by 1224.56% in 2022, and later tumbled by 6334.53% in 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Equity Ratio (Quarter) stood at 0.53 in 2021, then increased by 12.25% to 0.59 in 2022, then grew by 5.86% to 0.63 in 2023, then rose by 10.28% to 0.69 in 2024, then plummeted by 64.48% to 0.25 in 2025.
- Its Equity Ratio stands at 0.25 for Q3 2025, versus 0.53 for Q2 2025 and 0.71 for Q1 2025.